Brian Haney, DO
Hematology & Oncology · Topsham, MENPI 1285830554
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,880 of the $11,961 with a category attached, or 74.2%. Daiichi Sankyo Inc. accounts for 75.1% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $9,082 and has fallen 96.3% since, to $340 in 2025.
Across 66 payments — averaging $181.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$9K
- Exelixis Inc.$2K
- AbbVie$173
- Pharmacyclics LLC, An Abbvie Company$147
- AstraZeneca$126
- Amgen$115
- plus $772 from 19 others
What the payments were for
- Consulting fees$8,88074%
- Speaking & faculty fees$1,65014%
- Food & beverage$1,33211%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 8 | $8,978 |
| Exelixis Inc. | 1 | $1,650 |
| AbbVie | 6 | $173 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $147 |
| AstraZeneca | 5 | $126 |
| Amgen | 4 | $115 |
| Johnson & Johnson(2 entities) | 4 | $102 |
| Coherus Oncology, Inc. | 1 | $89 |
| Incyte Corporation | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Pfizer | 4 | $68 |
| Merck | 3 | $57 |
| ADC Therapeutics America, Inc. | 2 | $47 |
| Genentech USA, Inc. | 2 | $38 |
| Novartis | 2 | $34 |
| GSK | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Immunomedics, Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabometyx$1,650
How this compares
$11,961 in reported general payments places this provider in the 80th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 74 | $1,316,569 |
| CalquenceAcalabrutinib Maleate | 52 | $673,215 |
| ErleadaApalutamide | 34 | $496,230 |
| PomalystPomalidomide | 20 | $411,053 |
| KisqaliRibociclib Succinate | 16 | $268,193 |
| Abiraterone Acetate | 79 | $246,282 |
| TasignaNilotinib Hcl | 12 | $237,977 |
| Lenalidomide | 20 | $223,229 |
| ImbruvicaIbrutinib | 13 | $212,772 |
| IbrancePalbociclib | 12 | $195,621 |
| NubeqaDarolutamide | 13 | $177,359 |
| LynparzaOlaparib | 12 | $168,815 |
| Lupron DepotLeuprolide Acetate | 15 | $92,056 |
| EliquisApixaban | 46 | $45,262 |
| EligardLeuprolide Acetate | 12 | $17,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $15 | $1,316,56974 claims |
| AstraZenecaCalquence, Lynparza | $126 | $842,03064 claims |
| NovartisKisqali, Tasigna | $34 | $506,17028 claims |
| Johnson & JohnsonErleada | $102 | $496,23034 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $21 | $411,05320 claims |
| PfizerIbrance, Eliquis | $68 | $240,88358 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $147 | $212,77213 claims |
| AbbVieLupron Depot, Creon | $173 | $104,03826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 60 hematology & oncology providers in Maine.
Other hematology & oncology in Topsham
- David BentonTopsham$3K
- Julia MoukharskayaTopsham$595
- Matthew DuganWestbrook$577K
- John WintersWestbrook$341K
- Helen RyanKennebunk$83K
- Eleni NackosWestbrook$79K
- Christian ThomasWestbrook$54K
- Devon EvansWestbrook$31K
- Tracey WeisbergWestbrook$31K
- Daniel RauschWestbrook$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.